Element Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Element Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,390	Closed	-$603K	–	811
2018 Q1	$603K	Buy	+10,390	New	+$647K	0.01%	275
2017 Q4	–	Sell	-3,535	Closed	-$129K	–	137
2017 Q3	$129K	Sell	3,535 -8,936	-72%	-$248K	0.05%	45
2017 Q2	$312K	Buy	+12,471	New	+$341K	0.06%	68

Other funds holding ADVM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Element Capital Management's ADVM Position: Q2 2018 in Review

Element Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2018, closing a stake of 10,390 shares — an estimated $603K sold.

Element Capital Management first reported a position in ADVM in Q2 2017 and held it in 3 quarters. The position peaked at $603K in Q1 2018. 100 funds tracked by Wall St. Rank hold ADVM as of Q2 2018.

Element Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2018 after selling out during the quarter.
Element Capital Management sold 10,390 Adverum Biotechnologies shares in Q2 2018, an estimated $603K.
Element Capital Management first reported a position in Adverum Biotechnologies in Q2 2017 and held it in 3 quarters.
Element Capital Management's Adverum Biotechnologies position peaked at $603K in Q1 2018.
100 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.